Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) presented new Phase 3 MURANO and CLL14 trial results at the 62nd ASH Annual Meeting, emphasizing the effectiveness of VENCLEXTA/VENCLYXTO in chronic lymphocytic leukemia (CLL). The MURANO trial showed a median progression-free survival (PFS) of 53.6 months with VenR versus 17.0 months with BR. The overall survival (OS) estimate was 82.1% for VenR compared to 62.2% for BR. In the CLL14 trial, uMRD levels indicated better PFS outcomes. These results highlight VENCLEXTA's potential to improve patient outcomes significantly.
AbbVie (NYSE: ABBV) presented new data from the Phase 2 CAPTIVATE trial at the 2020 ASH Annual Meeting, showcasing the efficacy of IMBRUVICA® (ibrutinib) combined with VENCLEXTA®/VENCLYXTO® (venetoclax) for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The results indicated a one-year disease-free survival (DFS) rate of 100% for patients receiving ibrutinib compared to 95.3% for placebo. This combination also demonstrated high rates of undetectable minimal residual disease (uMRD). The study's findings support a potential fixed-duration treatment option for CLL/SLL patients.
AbbVie and Frontier Medicines announced a strategic collaboration to discover and develop innovative small molecule therapeutics targeting challenging protein targets in oncology and immunology. AbbVie will provide an upfront payment of $55 million and cover R&D costs during pre-clinical development phases. The collaboration has the potential for milestone payments exceeding $1 billion and expanded target options. AbbVie aims to enhance its efforts in targeted protein degradation while Frontier retains rights to its internal programs.
AbbVie (NYSE: ABBV) and Frontier Medicines have entered a strategic collaboration aimed at discovering and commercializing small molecule therapeutics targeting challenging protein targets, especially in oncology and immunology.
AbbVie will provide an upfront payment of $55 million and cover Frontier's R&D costs through early development phases. Frontier can receive additional milestone payments, potentially exceeding $1 billion, as well as royalties on commercialized products. This partnership enhances AbbVie's focus on innovative drug development, particularly in protein degradation.
AbbVie will conduct a virtual immunology strategic update for investors on December 14, 2020, at 9:00 a.m. Central time. Richard A. Gonzalez, CEO, alongside the executive leadership team, will discuss AbbVie's immunology business and pipeline. Investors can access a live audio webcast on AbbVie's Investor Relations site, with an archived version available later that day. AbbVie's mission focuses on developing innovative medicines across various therapeutic areas, including immunology, oncology, and more.
AbbVie (NYSE: ABBV) will participate in the Evercore ISI Virtual HealthCONx Conference on December 2, 2020, at 1:40 p.m. CT, and the Piper Sandler Virtual Healthcare Conference on December 3, 2020, at 10 a.m. CT. Key executives, including Michael Severino, M.D., and Robert A. Michael, will present at both venues. Investors can access a live audio webcast from AbbVie's Investor Relations website, with archived versions available later that day. AbbVie's mission focuses on delivering innovative medicines across various therapeutic areas.
AbbVie announced the expiration and results of its Registered Exchange Offers for its outstanding senior unsecured notes totaling $30 billion and €2.5 billion. The offers concluded on November 17, 2020, with an impressive participation rate across multiple notes, notably a 100% exchange of the Senior Floating Rate Notes due November 2021. The company is set to settle the exchanges on November 19, 2020. The new Registered Notes will have similar terms to the Original Notes but will be registered under the Securities Act, eliminating certain transfer restrictions.
Summary not available.
AbbVie will participate in the Wolfe Research Healthcare Conference on November 19, 2020. Presenters include Michael Severino, vice chairman and president, and Robert A. Michael, CFO, scheduled for 11:35 a.m. Central time. A live audio webcast will be available on AbbVie’s Investor Relations website, with an archived version accessible later the same day.
AbbVie focuses on delivering innovative medicines across various therapeutic areas, including immunology and oncology.
AbbVie (NYSE: ABBV) will present nearly 40 abstracts, including 10 oral presentations, at the virtual American Society of Hematology (ASH) Annual Meeting from December 5-8, focusing on blood cancers.
Key studies include updated results from the CAPTIVATE study on chronic lymphocytic leukemia (CLL) treatments and data from collaborations with Genmab and I-Mab. Notable presentations involve long-term efficacy analyses and real-world patient data on therapies like Ibrutinib and Venetoclax.